Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd

Lenneke F J Groningen, Christoph Groth, MD, Manita E J Bremmers, Eric G Hooren, Ypke V J M van Oosterhout, Nicole M A Blijlevens, Matthias Stelljes, Walter J F M van der Velden

Blood (2019) 134 (Supplement_1): 4553.

https://doi.org/10.1182/blood-2019-122923

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Non-Genotoxic Conditioning Efficiently Depletes Host Hematopoietic Stem Cells and Facilitates Robust Multi-Lineage Engraftment in a Mouse Model of Fanconi Anemia

Meera Srikanthan, MD, Kevin G. Haworth, PhD, Christina M. Ironside, BS, Jerry Chen, Adam J. Hartigan, PhD, Rahul Palchaudhuri, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Hans-Peter Kiem, MD PhD

Blood (2018) 132 (Supplement 1): 2041.

https://doi.org/10.1182/blood-2018-99-116851

Published: 2018

Journal Articles

Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells

Youmna Kfoury, PhD, Esha Jain, Jason R Myers, MS, Fei Ji, David B Sykes, MD PhD, Francois Mercier, MD FRCPC, Ani Papazian, BS, Cam Le, Mark A Randolph, M.A.Sc., David P. Steensma, MD, Omar I Abdel-Wahab, MD, Laura M. Calvi, MD, Ruslan I Sadreyev, PhD, Michael W. Becker, MD, David T. Scadden, MD

Blood (2018) 132 (Supplement 1): 938.

https://doi.org/10.1182/blood-2018-99-115242

Published: 2018

Journal Articles

Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1 -Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)

Blood (2018) 132 (Supplement 1): 991.

https://doi.org/10.1182/blood-2018-99-114648

Published: 2018

Journal Articles

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Parayath Neha, Mansoor Amiji, Nikhil Munshi, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2018-99-117292

Published: 2018

Journal Articles

Skewed HSC Clonal Output of T-Cells in an Aged Rhesus Macaque after CD3e-Immunotoxin Treatment

Sanggu Kim, PhD, Gajendra Suryavanshi, PhD, Aylin Bonifacino, MS, Chuanfeng Wu, MD, Cynthia E Dunbar, MD, Robert E Donahue, VMD, Irvin Chen, PhD

Blood (2017) 130 (Supplement 1): 3758.

https://doi.org/10.1182/blood.V130.Suppl_1.3758.3758

Published: 2017

Journal Articles

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Bartosz Grzywacz, MD, Elizabeth L. Courville, MD, David H. McKenna, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD, Laura Moench, MD

Blood (2017) 130 (Supplement 1): 4459.

https://doi.org/10.1182/blood.V130.Suppl_1.4459.4459

Published: 2017

Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD

Blood (2017) 130 (Supplement 1): 2765.

https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765

Published: 2017

Journal Articles

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, John Mark Sloan, MD, Anas Younes, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 5212.

https://doi.org/10.1182/blood.V130.Suppl_1.5212.5212

Published: 2017

Journal Articles

A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd

Christoph Groth, MD, Lenneke F J Groningen, Manita E J Bremmers, Frank W M B Preijers, Harry Dolstra, Tiago R Matos, Christian Reicherts, Eric G van Hooren, Ypke V J M van Oosterhout, John E Levine, MD, James L Ferrara, Nicole M A Blijlevens, Matthias Stelljes, MD, Walter J F M van der Velden

Blood (2017) 130 (Supplement 1): 513.

https://doi.org/10.1182/blood.V130.Suppl_1.513.513

Published: 2017

Journal Articles

Immunotoxin Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemic Cells

Thierry Guillaume, MD PhD, Virginie Dehame, MSc, Patrice Chevallier, MD, Pierre Peterlin, MD, Marc Gregoire, PhD, Daniel Rubinstein, MD, Eddy Pichinuk, PhD, Daniel H Wreschner, MD

Blood (2017) 130 (Supplement 1): 5060.

https://doi.org/10.1182/blood.V130.Suppl_1.5060.5060

Published: 2017

Journal Articles

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Weili Sun, Meina Liang, Jie Yang, Robert J. Kreitman, Mark C. Lanasa, Ira Pastan

Blood (2017) 130 (14): 1620–1627.

https://doi.org/10.1182/blood-2017-02-749101

Published: 2017

Includes: Supplemental data

Journal Articles

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, Anas Younes, MD

Blood (2016) 128 (22): 4200.

https://doi.org/10.1182/blood.V128.22.4200.4200

Published: 2016

Journal Articles

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Fabian Mueller, MD, Tyler Cunningham, Stephanie Stookey, Chin-Hsien Tai, Alan S. Wayne, MD, Ira Pastan, MD

Blood (2016) 128 (22): 2810.

https://doi.org/10.1182/blood.V128.22.2810.2810

Published: 2016

Journal Articles

Elimination of FVIII-Specific B Cells By Immunotoxins Comprised of a Single FVIII Domain Fused to Pseudomonas Exotoxin a

Kerstin Brettschneider, Anja Schmidt, PhD, Joerg Kahle, PhD, Aleksander Orlowski, Diana Stichel, Karin Becker-Peters, Sonja Neimanis, PhD, Christine Heller, MD, Thomas Klingebiel, MD, Dirk Schwabe, MD, Christoph Koenigs, MD PhD

Blood (2016) 128 (22): 561.

https://doi.org/10.1182/blood.V128.22.561.561

Published: 2016

Journal Articles

Enhanced Allogeneic Engraftment Achieved Via Prenatal Tolerance Induction and Postnatal Anti-CD45 Immunotoxin Conditioned Hematopoietic Cell Transplantation

Patrick E. McGovern, MD, Agnieszka Czechowicz, MD PhD, Ali Mejaddam, MD, John D. Stratigis, MD, Haiying Li, John Urwin, Lauren E. McClain, MD, Philip W. Zoltick, MD, Alan W. Flake, MD, William H. Peranteau, MD

Blood (2016) 128 (22): 2153.

https://doi.org/10.1182/blood.V128.22.2153.2153

Published: 2016

Journal Articles

Everolimus Is Active in Pretreated Hodgkin Lymphoma after Failure of Brentuximab Vedotin: Single Institute Experience

Reyad Dada, Associate Professor, MD, Fawwaz Yassin, MD

Blood (2016) 128 (22): 5368.

https://doi.org/10.1182/blood.V128.22.5368.5368

Published: 2016

Journal Articles

Completely Non-Myeloablative/Non-Lymphoablative Conditioning for BMT/HSCT Using Anti-Ckit Immunotoxins

Agnieszka Czechowicz, MD PhD, Rahul Palchaudhuri, PhD, Amelia Scheck, BS, Jonathan Hoggatt, PhD, Borja Saez, PhD, David T. Scadden, MD, Derrick J. Rossi, PhD

Blood (2016) 128 (22): 493.

https://doi.org/10.1182/blood.V128.22.493.493

Published: 2016

NARROW

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Non-Genotoxic Conditioning Efficiently Depletes Host Hematopoietic Stem Cells and Facilitates Robust Multi-Lineage Engraftment in a Mouse Model of Fanconi Anemia

Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells

Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1 -Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG)

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Skewed HSC Clonal Output of T-Cells in an Aged Rhesus Macaque after CD3e-Immunotoxin Treatment

NK Cell Homing and Persistence in Bone Marrow after Adoptive Immunotherapy Correlates with Therapy Response

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)

A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd

Immunotoxin Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemic Cells

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

5-Azacytidine Prevents Relapse from Discrete Bone Marrow Sites in Leukemia Xenografts Treated with CD22-Targeting Immunotoxin Moxetumomab Pasudotox

Elimination of FVIII-Specific B Cells By Immunotoxins Comprised of a Single FVIII Domain Fused to Pseudomonas Exotoxin a

Enhanced Allogeneic Engraftment Achieved Via Prenatal Tolerance Induction and Postnatal Anti-CD45 Immunotoxin Conditioned Hematopoietic Cell Transplantation

Everolimus Is Active in Pretreated Hodgkin Lymphoma after Failure of Brentuximab Vedotin: Single Institute Experience

Completely Non-Myeloablative/Non-Lymphoablative Conditioning for BMT/HSCT Using Anti-Ckit Immunotoxins

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only